This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Portfolio Pulse from Avi Kapoor
Top Wall Street analysts initiated coverage on several companies, including Alumis Inc., Enliven Therapeutics, Intensity Therapeutics, Terns Pharmaceuticals, and Braze. Notably, Alumis received an Outperform rating with a $25 price target, while Braze was rated Neutral with a $30 target.
October 31, 2024 | 3:37 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Macquarie initiated coverage on Braze with a Neutral rating and a $30 price target, suggesting a cautious outlook.
The Neutral rating and a price target slightly below the current share price suggest a cautious outlook, which may lead to limited short-term price movement.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 100
POSITIVE IMPACT
Baird analyst initiated coverage on Alumis Inc. with an Outperform rating and a $25 price target, suggesting a positive outlook.
The Outperform rating and a price target significantly above the current share price suggest a strong positive sentiment from the analyst, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Jones Trading analyst initiated coverage on Enliven Therapeutics with a Buy rating and a $36 price target, indicating a positive outlook.
The Buy rating and a price target above the current share price suggest a positive outlook, which may attract investors and potentially increase the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
HC Wainwright & Co. analyst initiated coverage on Intensity Therapeutics with a Buy rating and a $5 price target, indicating a positive outlook.
The Buy rating and a price target above the current share price suggest a positive sentiment, which could lead to increased investor interest and a potential rise in the stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Oppenheimer analyst initiated coverage on Terns Pharmaceuticals with an Outperform rating and a $17 price target, suggesting a positive outlook.
The Outperform rating and a price target significantly above the current share price indicate a strong positive sentiment, likely to attract investors and potentially drive the stock price up.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100